Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl) pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile

Journal of Medicinal Chemistry

Volumn 54, Issue 13, 2011, Pages 4324-4338

  Zhang, Hai ^a   Ye, Na ^b   Zhou, Shanglin ^c   Guo, Lin ^c   Zheng, Longtai ^a   Liu, Zhili ^b   Gao, Bo ^a   Zhen, Xuechu ^a,c   Zhang, Ao ^b  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b Synthetic Organic and Medicinal Chemistry Laboratory (SOMCL)   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 3 [(N PROPYLNORAPORPHIN 11 YL)METHYL]UREA; 11 [2 (PHENYLTHIO)ACETYLOXY] N PROPYLNORAPORPHINE; 11 [5 (1,2 DITHIOLAN 3 YL)PENTYLOXY] N PROPYLNORAPORPHINE; 11 AMINO N PROPYLNORAPORPHINE; 11 AMINOMETHYL N PROPYLNORAPORPHINE; 11 CYANO N PROPYLNORAPORPHINE; 5 (1,2 DITHIOLAN 3 YL) N (N PROPYLNORAPORPHIN 11 YL)PENTANAMIDE; 5 (1,2 DITHIOLAN 3 YL) N [(N PROPYLNORAPORPHIN 11 YL)]PENTANAMIDE; 5 [4 (1,2 DITHIOLAN 3 YL)BUTYL] 3 (N PROPYLNORAPORPHIN 11 YL) 1,2,4 OXADIAZOLE; ADRENALIN; ANTIPARKINSON AGENT; APORPHINE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; N PROPYLNORAPORPHIN 11 YL TERT BUTYLCARBAMIC ACID; N PROPYLNORAPORPHIN 11 YLBENZYLCARBAMIC ACID; N PROPYLNORAPORPHIN 11 YLBUTYLCARBAMIC ACID; N PROPYLNORAPORPHIN 11 YLBUTYRAMIDE; N PROPYLNORAPORPHIN 11 YLETHYLCARBAMIC ACID; N PROPYLNORAPORPHIN 11 YLNAPHTHALEN 1 YLCARBAMIC ACID; N PROPYLNORAPORPHIN 11 YLPROPYLCARBAMIC ACID; POSTSYNAPTIC RECEPTOR; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; TRANSCRIPTION FACTOR FOSB; UNCLASSIFIED DRUG; VALERIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CHO CELL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DYSKINESIA; LONG TERM CARE; MALE; NONHUMAN; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIPARKINSON AGENTS; APORPHINES; BINDING, COMPETITIVE; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CRICETULUS; DYSKINESIA, DRUG-INDUCED; HEK293 CELLS; HUMANS; LEVODOPA; OXIDOPAMINE; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-FOS; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE D2; SEROTONIN 5-HT1 RECEPTOR AGONISTS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOCTIC ACID;

EID: 79960151499     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200347t     Document Type: Article

References (72)

1. Lilienfeld, D. E.; Perl, D. P. Projected neurodegenerative disease mortality in the United States, 1990-2040 Neuroepidemiology 1993, 12, 219-228 (Pubitemid 23353340)
2. Schapira, A. H. Neurobiology and treatment of Parkinson's disease Trends Pharmacol. Sci. 2009, 30, 41-47
3. Schapira, A. H. Etiology and pathogenesis of Parkinson disease Neurol. Clin. 2009, 27, 583-603
4. Schapira, A. H.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G. L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Le Novere, N.; Obeso, J. A.; Schwarzschild, M. A.; Spampinato, U.; Davidai, G. Novel pharmacological targets for the treatment of Parkinson's disease Nat. Rev. Drug Discovery 2006, 5, 845-854 (Pubitemid 44480538)
5. Schapira, A. H. Future directions in the treatment of Parkinson's disease Mov. Disord. 2007, 22 (Suppl. 17) S385-S391
6. Nagatsu, T.; Sawada, M. L-dopa therapy for Parkinson's disease: Past, present, and future Parkinsonism and Related Disorders 2009, 15 (Suppl. 1) S3-S8
7. Calabresi, P.; Di Filippo, M.; Ghiglieri, V.; Picconi, B. Molecular mechanisms underlying levodopa-induced dyskinesia Mov. Disord. 2008, 23 (Suppl. 3) S570-S579
8. Abbott, A. Levodopa: The story so far Nature 2010, 466 (7310) S6-S7
9. Lieberman, J. A. Dopamine partial agonists: A new class of antipsychotic CNS Drugs 2004, 18, 251-267 (Pubitemid 38393435)
10. Yamamoto, M.; Schapira, A. H. Dopamine agonists in Parkinson's disease Expert Rev. Neurother. 2008, 8, 671-677 (Pubitemid 351551017)
11. Rezak, M. Current pharmacotherapeutic treatment options in Parkinson's disease DM, Dis.-Mon. 2007, 53, 214-222 (Pubitemid 46935688)
12. Stocchi, F. Dopamine receptor agonists in the treatment of advanced Parkinson's disease Parkinsonism and Related Disorders 2009, 15 (Suppl. 4) S54-S57
13. Nutt, J. G.; Obeso, J. A.; Stocchi, F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease Trends Neurosci. 2000, 23 (Suppl. 10) S109-S115
14. Olanow, C. W.; Schapira, A. H.; Rascol, O. Continuous dopamine-receptor stimulation in early Parkinson's disease Trends Neurosci. 2000, 23 (Suppl. 10) S117-S126
15. Abdel-Salam, O. M. Drugs used to treat Parkinson's disease, present status and future directions CNS Neurol. Disord.: Drug Targets 2008, 7, 321-342
16. Gottwald, M. D.; Aminoff, M. J. New frontiers in the pharmacological management of Parkinson's disease Drugs Today 2008, 44, 531-545
17. 1A receptors in central nervous system disorders Cent. Nerv. Syst. Agents Med. Chem. 2010, 10, 148-157
18. Politis, M.; Wu, K.; Loane, C.; Quinn, N. P.; Brooks, D. J.; Rehncrona, S.; Bjorklund, A.; Lindvall, O.; Piccini, P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants Sci. Transl. Med. 2010, 2, 38-46
19. Santiago, M.; Matarredona, E. R.; Machado, A.; Cano, J. Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum J. Neurosci. Res. 1998, 52, 591-598 (Pubitemid 28252740)
20. Antonelli, T.; Fuxe, K.; Tomasini, M. C.; Bartoszyk, G. D.; Seyfried, C. A.; Tanganelli, S.; Ferraro, L. Effects of sarizotan on the corticostriatal glutamate pathways Synapse 2005, 58, 193-199 (Pubitemid 41443739)
21. 1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat Neuropharmacology 2008, 55, 1321-1328
22. 1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats J. Neurosci. Res. 2009, 87, 1645-1658
23. 2 receptor ligand Drugs Future 2006, 31, 314-319
24. Sorbera, L. A.; Castaner, J. Bifeprunox mesylate Drugs Future 2005, 30, 992-997
25. 1A receptors Future Neurol. 2007, 2, 153-165
26. Bronzova, J.; Sampaio, C.; Hauser, R. A.; Lang, A. E.; Rascol, O.; Theeuwes, A.; van de Witte, S. V.; van Scharrenburg, G. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease Mov. Disord. 2010, 25, 730-738
27. Goetz, C. G.; Damier, P.; Hicking, C.; Laska, E.; Muller, T.; Olanow, C. W.; Rascol, O.; Russ, H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial Mov. Disord. 2007, 22, 179-186 (Pubitemid 46374758)
28. 1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 2001, 57, 1829-1834 (Pubitemid 33096691)
29. Tillner, J.; Krosser, S.; Fluck, M.; Ungethum, W.; Kovar, A. Sarizotan: A review of its clinical pharmacokinetics Mov. Disord. 2006, 21 (Suppl. 13) Abstract P234
30. 2-like dopamine receptors Neuropharmacology 2006, 51, 873-884 (Pubitemid 44308342)
31. 1A receptor agonist Synapse 2006, 60, 599-608 (Pubitemid 44658266)
32. Neumeyer, J. L. Synthesis and structure-activity relationships of aporphines as dopamine receptor agonists and antagonists. In The Chemistry and Biology of Isoquinoline Alkaloids; Phillipson, J. D.; Roberts, M. F.; Zenk, M. H., Eds.; Springer-Verlag: Berlin, 1985; pp 146-170.
33. Zhang, A.; Neumeyer, J. L.; Baldessarini, R. J. Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders Chem. Rev. 2007, 107, 274-302 (Pubitemid 46237370)
34. Zhang, A.; Zhang, Y.; Branfman, A. R.; Baldessarini, R. J.; Neumeyer, J. L. Advances in development of dopaminergic aporphinoids J. Med. Chem. 2007, 50, 171-181 (Pubitemid 46147697)
35. 1A receptor agonist J. Med. Chem. 2010, 53, 1319-1328
36. Cannon, J. G.; Mohan, P.; Bojarski, J.; Long, J. P.; Bhatnagar, R. K.; Leonard, P. A.; Flynn, J. R.; Chatterjee, T. K. (R)-(-)-10-Methyl-11- hydroxyaporphine: A highly selective serotonergic agonist J. Med. Chem. 1988, 31, 313-318 (Pubitemid 18045355)
37. 1A receptors Chirality 1991, 3, 19-23
38. Hedberg, M. H.; Johansson, A. M.; Hacksell, U. Facile synthesis of aporphine derivatives J. Chem. Soc., Chem. Commun. 1992, 11, 845-846
39. 1A receptor interactions J. Med. Chem. 1995, 38, 647-658
40. 1A receptor interactions J. Med. Chem. 1996, 39, 3491-3502 (Pubitemid 26307854)
41. 1A receptor dual ligands Bioorg. Med. Chem. 2008, 16, 8335-8338
42. Liu, Z.; Chen, X.; Yu, L.; Zhen, X.; Zhang, A. Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines Bioorg. Med. Chem. 2008, 16, 6675-6681
43. Neumeyer, J. L.; Granchelli, F. E. Aporphines. 11. Synthesis and dopaminergic acitivity of monohydroxyaporphines. Total synthesis of (±)-11-hydroxyaporphine, (±)-11-hydroxynoraporphine, and (±)-11-hydroxy-N-n-propylnoraporphine J. Med. Chem. 1974, 17, 1090-1095
44. Nechab, M.; Kumar, D. N.; Philouze, C.; Einhorn, C.; Einhorn, J. Variable C2-symmetric analogues of N-hydroxyphthalimide as enantioselective catalysts for aerobic oxidation: Kinetic resolution of oxazolidines Angew. Chem., Int. Ed. 2007, 46, 3080-3083 (Pubitemid 46973522)
45. Minkkila, A.; Myllymaki, M. J.; Saario, S. M.; Castillo-Melendez, J. A.; Koskinen, A. M.; Fowler, C. J.; Leppanen, J.; Nevalainen, T. The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors Eur. J. Med. Chem. 2009, 44, 2994-3008
46. Zhang, J.; Chen, X.; Zhen, X.; Zhang, A. Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, March 22-26, 2009, MEDI-311.
47. Neumeyer, J. L.; Baldessarini, R. L. R-(-)-11-Hydroxyaporphine and derivatives thereof. U.S. Patent US2010081651, 2010.
48. Li, F.; Zhu, Q.; Zhang, Y.; Feng, Y.; Leng, Y.; Zhang, A. Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl- 3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators Bioorg. Med. Chem. 2010, 18, 3875-3884
49. Zhang, A.; Neumeyer, J. L. Microwave-promoted Pd-catalyzed cyanation of aryl triflates: A fast and versatile access to 3-cyano-3-desoxy-10- ketomorphinans Org. Lett. 2003, 5, 201-203 (Pubitemid 37141220)
50. 2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines J. Med. Chem. 2009, 52, 33-47
51. Perrone, R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.; Tortorella, V. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: A potent and selective dopamine D4 ligand J. Med. Chem. 1998, 41, 4903-4909 (Pubitemid 28530465)
52. Khelili, S.; Florence, X.; Bouhadja, M.; Abdelaziz, S.; Mechouch, N.; Mohamed, Y.; de Tullio, P.; Lebrun, P.; Pirotte, B. Synthesis and activity on rat aorta rings and rat pancreatic β-cells of ring-opened analogues of benzopyran-type potassium channel activators Bioorg. Med. Chem. 2008, 16, 6124-6130 (Pubitemid 351766719)
53. Koufaki, M.; Kiziridi, C.; Alexi, X.; Alexis, M. N. Design and synthesis of novel neuroprotective 1,2-dithiolane/chroman hybrids Bioorg. Med. Chem. 2009, 17, 6432-6441
54. Olesen, P. H. The use of bioisosteric groups in lead optimization Curr. Opin. Drug Discovery Dev. 2001, 4, 471-478 (Pubitemid 32678536)
55. Packer, L.; Witt, E. H.; Tritschler, H. J. α-Lipoic acid as a biological antioxidant Free Radical Biol. Med. 1995, 19, 227-250
56. Tirosh, O.; Sen, C. K.; Roy, S.; Kobayashi, M. S.; Packer, L. Neuroprotective effects of α-lipoic acid and its positively charged amide analogue Free Radical Biol. Med. 1999, 26, 1418-1426 (Pubitemid 29308022)
57. Biewenga, G. P.; Haenen, G. R.; Bast, A. The pharmacology of the antioxidant lipoic acid Gen. Pharmacol. 1997, 29, 315-331
58. Packer, L. R-Lipoic acid: A metabolic antioxidant which regulates NF-κB signal transduction and protects against oxidative injury Drug Metab. Rev. 1998, 30, 245-275 (Pubitemid 28266862)
59. Di Stefano, A.; Sozio, P.; Cocco, A.; Iannitelli, A.; Santucci, E.; Costa, M.; Pecci, L.; Nasuti, C.; Cantalamessa, F.; Pinnen, F. J. Med. Chem. 2006, 49, 1486-1493
60. 3H]quinpirole binding in brain by monoamine oxidase inhibitors: Evidence for a potential novel binding site J. Pharmacol. Exp. Ther. 1996, 278, 145-153 (Pubitemid 27167089)
61. Ziolkowski, N.; Grover, A. K. Functional linkage as a direction for studies in oxidative stress: α-Adrenergic receptors Can. J. Physiol. Pharmacol. 2010, 88, 220-232
62. Ruffolo, R. R., Jr.; Bondinell, W.; Hieble, J. P. α- and β-adrenoceptors: From the gene to the clinic. 2. Structure-activity relationships and therapeutic applications J. Med. Chem. 1995, 38, 3681-3690
63. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) Pharmacol. Rev. 1994, 46, 157-203 (Pubitemid 24185150)
64. 1A receptors J. Med. Chem. 1993, 36, 1509-1510 (Pubitemid 23164512)
65. Carta, A. R.; Frau, L.; Pinna, A.; Pontis, S.; Simola, N.; Schintu, N.; Morelli, M. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat Synapse 2008, 62, 524-533 (Pubitemid 351794179)
66. Mo, J.; Zhang, H.; Yu, L. P.; Sun, P. H.; Jin, G. Z.; Zhen, X. L-Stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease Neurobiol. Aging 2010, 31, 926-936
67. 1 recognition site Eur. J. Pharmacol. 1983, 90, 151-153 (Pubitemid 13101524)
68. Andersson, M.; Hilbertson, A.; Cenci, M. A. Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease Neurobiol. Dis. 1999, 6, 461-474 (Pubitemid 30036616)
69. Cenci, M. A.; Lundblad, M. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia J. Neurochem. 2006, 99, 381-392 (Pubitemid 44477196)
70. Pavon, N.; Martin, A. B.; Mendialdua, A.; Moratalla, R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice Biol. Psychiatry 2006, 59, 64-74 (Pubitemid 43005237)
71. Zhang, H.; Ma, L.; Wang, F.; Chen, J.; Zhen, X. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease Neuropharmacology 2007, 53, 125-133 (Pubitemid 47125943)
72. Guo, J. D.; Rainnie, D. G. Presynaptic 5-HT(1B) receptor-mediated serotonergic inhibition of glutamate transmission in the bed nucleus of the stria terminalis Neuroscience 2010, 165, 1390-1401